Background Preoperative diagnosis of malignancy in pancreatic cystic lesions (PCLs) remains challenging. Most non-mucinous cystic lesions (NMCLs) are benign, but mucinous cystic lesions (MCLs) are more likely to be premalignant or malignant. Aim The aim of this study was to assess the sensitivity, specificity, and positive and negative likelihood ratios (LRs) of EUS-FNA-based cytology in differentiating MCLs from non-mucinous PCLs. Methods We conducted a comprehensive search of MEDLINE, SCOPUS, Cochrane, and ''CINAHL Plus'' databases to identify studies, in which the results of EUS-FNA-based cytology of PCLs were compared with those of surgical biopsy or surgical excision histopathology. A DerSimonian-Laird random effect model was used to estimate the pooled sensitivity, specificity, and LRs, and a summary receiver-operating characteristic (SROC) curve was constructed. Results We included 376 patients from 11 distinct studies who underwent EUS-FNA-based cytology and also had histopathological diagnosis. The pooled sensitivity and specificity in diagnosing MCLs were 0.63 (95% CI, 0.56-0.70) and 0.88 (95% CI, 0.83-0.93), respectively. The positive and negative LRs in diagnosing MCLs were 4.46 (95% CI, 1.21-16.43) and 0.46 (95% CI, 0.25-0.86), respectively. The area under the curve (AUC) was 0.89. Conclusions EUS-FNA-based cytology has overall low sensitivity but good specificity in differentiating MCLs from NMCLs. Further research is required to improve the overall sensitivity of EUS-FNA-based cytology to diagnose MCLs while evaluating PCL. 
Introduction
Pancreatic cystic lesions (PCLs) comprise a variety of pathologically different groups of lesions that usually share many common clinical features [1] [2] [3] [4] . About 90% of PCLs are benign processes such as pseudocysts related to acute or chronic pancreatitis [4] [5] [6] . Pancreatic cystic neoplasms (PCNs) constitute 10-15% of all PCLs and less than 1% of all pancreatic neoplasms [3, 7] . PCLs can be broadly classified into mucinous cystic lesions (MCLs) and nonmucinous cystic lesions (NMCLs). NMCLs include entities such as pseudocysts (PCs), serous cyst adenomas (SCAs), solid pseudopapillary tumors (SPTs), and pancreatic endocrine tumors (PETs). MCLs are classified into benign, borderline, and malignant tumors based on the degree of epithelial dysplasia [8] [9] [10] . Though MCLs can be benign, they are more likely to be premalignant or malignant; and early resection can provide excellent prognosis [3, 11, 12] . In the past decade, endoscopic ultrasound (EUS) has been increasingly used as a diagnostic tool for PCNs, as it can provide high-resolution images of PCLs and also enable EUS-guided FNA of pancreatic cystic fluid [13] . Despite advances in diagnostic modalities like EUS and cyst fluid analysis by EUS FNA, preoperative diagnosis of cystic lesions remains difficult.
Materials and Methods

Search Strategy
We performed a systematic literature review by using the guidelines developed for conducting systematic review [14] . A comprehensive search of the MEDLINE (PubMed and Ovid from 1966 to October 2008), SCOPUS (consisting of Medline and Embase databases), Cochrane Database of Systemic Reviews, and ''CINAHL Plus'' databases, was conducted using four combinations of search terms: (a) pancreatic cyst, endoscopy, FNA; (b) EUS AND pancreas AND cyst; (c) EUS, FNA, pancreatic cystic neoplasm; and (d) pancreatic cystic tumors AND EUS. Our search was restricted to human subjects and Englishlanguage studies. Outcomes: Results reported in sufficient details to construct a diagnostic 2 9 2 table (true-positive, false-positive, true-negative, and false -negative).
Exclusion Criteria
We excluded case reports and case series; studies in which EUS-FNA was done for solid pancreatic lesions, with or without cystic component; studies that included both cystic and solid pancreatic lesions; studies that included clinical follow-up as a criterion standard without knowing the disease status based on surgical pathology; studies that included other FNA approaches, like CT guided FNA or ultrasound guided FNA, in reporting their final results; and studies that did not provide data sufficient to construct a diagnostic 2 9 2 table.
Histological Criteria
Based on WHO tumor classifications, we classified all PCLs as either MCLs or non-mucinous cystic lesions. All cystic lesions arising from intraductal papillary neoplasms also were classified as MCLs.
Data Abstraction
From the selected studies, two independent reviewers (N.T. and S.T.) extracted the following data onto standardized data forms (in Microsoft Excel TM ):
• Study characteristics: design, country, year of publication, setting, sample size, clinical context, and criterion standard • Demographic characteristics: mean age, proportion of male and female, and prevalence of MCLs out of total PCLs • Interventions: manufacture and operating frequencies of endoscope, gauge size, length, manufacturer of EUS-FNA needles, and cyto-pathological staining methods • Outcomes: number of true-positive, true-negative, false-positive, and false-negative for MCLs of pancreas Discrepancies were resolved by discussion and consensus with a third reviewer (S.G.).
Quality Criteria
Current quality assessment guidelines and tools focus on randomization, selection bias of the arms in the study, concealment of allocation, and blinding of outcome to evaluate the quality of the clinical trials with control arm [15] . There is no consensus or criteria to evaluate the quality of the studies without a control arm [15] . Almost all of the studies focusing on the accuracy of EUS-FNA-based cytology in PCLs are either retrospective or prospective studies without control arm. Therefore, for this systematic review and meta-analysis we selected studies based on our pre-defined inclusion and exclusion criteria and completeness of data reporting in the studies.
Statistical Analysis
We constructed a 2 9 2 table for each study; for studies in which 0 counts occurred in study data, a continuity correction of 0.5 was added to every value in that study in order to calculate sensitivity and specificity. Based on the 2 9 2 table, we calculated the true-positive, false-positive, true-negative, and false-negative values and entered these into the statistical software package Meta-Disc version 1.4 (Meta-Disc, Unit of Clinical Biostatistics team of the Roman y Cajal Hospital, Madrid, Spain) [16] . We calculated the sensitivity, specificity, positive LR, negative LR, and diagnostic odds ratio (DOR: positive LR/negative LR) for each study and then pooled the results as per the DerSimonianLiard random effects model [17] . Meta-Disc version 1.4 was used to generate Forest plots of sensitivity, specificity, positive LRs, and negative LRs. We performed subgroup analysis and calculated sensitivity, specificity, positive LRs and negative LRs for subgroup of four prospective studies.
Heterogeneity was assessed by using v 2 statistics [18, 19] . By using DerSimonian-Liard random effects model, we constructed a summary receiver operating characteristic curve (SROC) [17] . The area under the curve (AUC) was computed by numeric integration of the SROC equation by using the trapezoidal method [20] . A preferred test has an AUC close to 1, and a poor test has an AUC close to 0.5. We used the random effect meta-regression analysis and Moses-Shapiro-Litternberg method [21] to examine study design (prospective vs. retrospective), single center vs. multicenter, sex ratio, sample size, and EUS FNA needle size for the heterogeneity analysis. The results of the meta-regression model were expressed as relative diagnostic odds ratio (RDOR) of the corresponding covariate [21] .
Results
Systematic Review
Description of Studies
Our study selection process is described in detail in Fig. 1 . Our initial search yielded 256 study titles and abstracts. Of these, 11 studies [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] met the pre-defined inclusion Fig. 1 Flow diagram of study selection process for the systematic review and meta-analysis and exclusion criteria and were selected for meta-analysis. Ten studies were from USA, and one was from France [24] . Seven studies were retrospective [22, 23, 26, [28] [29] [30] [31] and four studies were prospective [24, 25, 27, 32] . Altogether, the studies reported on 937 patients (361 male and 576 female). The mean age was 59 years. Of 937 total patients, EUS-FNA of PCLs had been performed on 788 patients and surgical biopsy or surgical resection had been performed on 446 patients. Of 446 patients with surgery, 70 patients underwent surgical resection based on clinical characteristics and EUS morphology without EUS-FNA and they were excluded from analysis. Similarly, of 788 patients with EUS-FNA, 412 did not receive a final diagnosis by surgical biopsy or resection and they were also excluded from analysis. This left 376 patients who received both a satisfactory EUS-FNA for cytological diagnosis and the gold standard comparison by either surgical histology or biopsy. The study characteristics of the included manuscripts are shown in Table 1 . Seven [22, 24, [29] [30] [31] [32] out of 11 studies further differentiated mucinous cysts into mucinous cyst adenoma, mucinous adenocarcinoma and intra papillary mucinous neoplasia. (Fig. 3) . The P value for v 2 heterogeneity for all the pooled estimates was less than 0.05 suggesting heterogeneity amongst the studies. To explore heterogeneity, we performed a subgroup analysis of four prospective studies. In subgroup analysis of four prospective studies, the pooled sensitivity of EUS-FNA-based cytology was 0.54 (95% CI, 0.45-0.62) and the pooled specificity was 0.92 (95% CI, 0.85-0.96) (Fig. 4) . Similarly, the pooled positive LR was 8.22 (95% CI, 0.82-82.36) and the pooled negative LR was 0.47 (95% CI, 0.20-1.12) (Fig. 5) . The overall accuracy of EUS in a SROC plot for meta-analysis and subgroup analysis is shown in Fig. 6 . The symmetric curve shows a trade-off between sensitivity and specificity. The AUC was 0.89 for all 11 studies and was 0.99 for four prospective studies, indicating high test accuracy.
Among the seven studies [22] [23] [24] [29] [30] [31] [32] (Table 2) .
We identified 13 potential sources of heterogeneity: (1) study design(prospective versus retrospective), (2) singlecenter versus multi-center, (3) sample size, (4) sex ratio, (5) cyst location, (6) cyst size, (7) EUS-FNA needle size, (8) average needle pass, (9) amount of the cyst fluid aspirated, (10) presence or absence of the cytopathologist at time of cyst aspiration, (11) average time from aspiration of cyst fluid to preparation of slide, (12) type and total number of histological stains are used, and (13) experience of the cytopathologist. However, the 11 primary studies provided data sufficient to analyze heterogeneity for only five of the 13 identified sources: study design, single-center versus multi-center, sample size, sex ratio, and EUS-FNA needle size. Meta-regression for study design, single-center versus multi-center, sample size, and sex ratio did not show any statistical significant difference. Of 11 studies, ten reported needle sizes for EUS-FNA. Meta-regression for needle size in these ten studies did not show statistically significant difference. The outcomes of the regression analysis as RDOR are shown in Table 3 .
Discussion
EUS-FNA has a diagnostic advantage over other FNA methods, including CT-guided FNA and US-guided FNA, that historically have been relatively unsuccessful as pancreatic cysts can be very small and inaccessible [33] [34] [35] . This systematic review of EUS-FNA-based cytology for patients who have PCLs found that EUS-FNA has good diagnostic accuracy, with an AUC of 0.89. Our metaanalysis showed EUS-FNA-based cytology to have a pooled sensitivity of 63% (95% CI, 0.56-0.70) and a pooled specificity of 88% (95% CI, 0.83-0.93). The subgroup analysis of four prospective studies showed sensitivity 0.54 (95% CI, 0.45-0.62) and specificity 0.92 (95% CI, 0.85-0.96). In our study, the positive and negative LRs were 4.93 (95% CI, 1.35-18.08) and 0.46 (95% CI, 0.27-0.80) respectively. Further, analysis of different mucinous cyst subtypes revealed EUS-FNA accurately diagnosed mucinous adenocarcinomas (100%) and IPMNs (72.91%) more frequently than it diagnosed MCAs (56.52%). The pooled sensitivity of 63% might be overestimated than the real sensitivity secondary to verification bias [36] . Verification bias occurs when out of all the patients who had diagnostic test only a subgroup of patient undergoes confirmatory test. Verification bias can be avoided by requiring everyone who enrolls in the study, to undergo confirmatory test (i.e., pancreatic cyst biopsy or surgical resection) irrespective of the positive or negative diagnostic test (i.e., EUS-FNA) result but this is not practical and ethical. It is reasonable to assume that patients with positive EUS-FNA-based cytology were more likely to undergo confirmatory test than the patients with negative EUS-FNA-based cytology raising the sensitivity of the diagnostic test. For the same reason, the pooled specificity of 88% might be underestimated than the real specificity. Further calculations for the verification bias were not possible secondary to lack of adequate reporting in the included studies.
Major pitfalls in diagnosis of PCLs by EUS-FNA include a high frequency of insufficient aspirates and difficulty in differentiating pathological mucin from gastrointestinal contaminant secondary to a transgastric or transduodenal approach of EUS-FNA. Most studies have shown that rapid on-site evaluation (ROSE) by the cytopathologist can help to assess adequacy of sample and also improve diagnostic yield of the procedure. A recent study by Hikichi et al. showed that even when a cytopathologist is not available, rapid on-site evaluation by an endosonographer is equally effective and helps to increase the diagnostic yield [37] . The presence of extra-cellular mucin or intracytoplasmic mucin within neoplastic cells aids in the diagnosis of mucinous neoplasms. Pathological mucin is grossly thicker and more viscid, and on air-dried DiffQuick stained smears or ethanol fixed Papanicolaou stained smears, it appears more abundant than gastrointestinal contaminant does. If only liquid based preparations are mad, then mucus is very difficult to appreciate. Frossard et al. [24] prepared cell blocks and used special mucin stains like hematoxylin-eosin-saffron, periodic acidSchiff, and Alcian Blue, in addition to routine Diff-Quick stained smears. They used the ThinPrep 2000 processor (Cytyc Corporation, Marlborough, MA) to concentrate scant fluids to generate mono-layered cell populations with cleaner backgrounds and had the same pathologist analyze all smears and biopsies. In this study, 67 patients met our inclusion criteria, and for this subset of patients, the EUS-FNA-based cytology had sensitivity and specificity of 100%; only one patient who had a MCA was diagnosed as having an IPMN. In contrast, Attasaranya et al. [30] prepared one air-dried, modified Giemsa stained smear, and one alcohol-fixed, Papanicolaou stained smear for on-site evaluation. Of the 48 aspirates taken, 14 were hypocellular to make an FNA diagnosis. They did not perform any mucin stains on any specimens. In their subset of 34 patients, the EUS-FNA-based cytology had sensitivity of 23% and a specificity of 71%. These conflicting results among these studies might suggest that presence of on-site cytopathologist, and a standardize protocol for smear stains combined with the use of special mucin stains and a ThinPrep 2000 processor can help to improve the diagnostic accuracy of EUS-FNA-based cytology. Our systematic review identified that current literature on diagnostic accuracy of EUS-FNA-based cytology for PCLs is limited and heterogeneous. There is no randomized clinical trial focusing on this issue. In our meta-analysis, heterogeneity is probably caused by factors that were inadequately reported in the 11 primary studies and, therefore, cannot be explored. These factors include cyst size and location, volume of the aspirated cyst fluid, presence of a cytopathologist in the endoscopy suite during the procedure, time interval from the aspiration of cyst fluid to the preparation of pathological slides, the methods of staining, and experience of cyto-pathologist. Although we were not able to demonstrate needle size as a significant factor for heterogeneity due to lack of adequate data reporting, a recent study by Song et al. clearly showed that for solid pancreatic lesions, EUS-FNA with a 19-gauge needle had significantly higher diagnostic accuracy compared to a 22-gauge needle (93.9 vs. 78.1, p \ 0.05) [37] . Also, the 19-gauge needle required a less number of needle passages and aspirated a significantly higher amount of cellular material [38] .
In addition to cytology, cyst-fluid analysis for tumor markers including CEA, CA 19-9, CA 72-4, CA 125, and molecular markers including K-ras mutations and loss of heterogeneity (LOH) was also performed in several studies [25, 27, 28] . Cooperative pancreatic cyst study reported that a cut-off value of 192 for CEA has the greatest AUC (0.79) for differentiation of mucinous versus non-mucinous PCLs [25] . The study also reported that CEA has greater accuracy, in diagnosing MCLs, than EUS morphology or cytology [25] . However, different studies reported different cut-off values for CEA analysis including 5, 148, 192, 300, 467, and 800 [25, 32, [38] [39] [40] [41] . Based on 36 cyst-fluid samples, Khalid et al. reported that occurrence of K-ras mutations as a first hit had sensitivity of 91% and specificity of 86%, whereas presence of allelic loss (measured by LOH) after K-ras mutations had sensitivity of 91% and specificity of 93%, respectively [27] . These studies show a promising role of CEA and molecular analysis in differentiating MCL from non-mucinous PCLs. CEA can be a very valuable tumor marker. However, more research is needed to define clear cut-off values for CEA. Initial studies on molecular analyses of pancreatic cancerassociated mutations of K-ras and other oncogenes/tumorsuppressor genes and expression of novel biomarkers are quite promising but more trials with larger sample sizes are needed in this direction.
In conclusion, based on the currently available Englishlanguage literature, our meta-analysis reveals that EUS-FNA-based cytology has overall low sensitivity but good specificity in differentiating mucinous from non-mucinous PCLs. Rapid on-site evaluation by a cytopathologist or an endosonographer, use of standardized techniques for smear staining, use of special mucin stains and use of the ThinPrep 2000 to provide a mono-layered cell populations with cleaner backgrounds can help to increase diagnostic yield of EUS-FNA-based cytology. Well-designed randomized trials are needed to further explore the role of EUS-FNAbased cytology in differentiating mucinous PLCs from nonmucinous PCLs. Further emphasis on the combined role of EUS morphology, FNA-based cytology, and cyst-fluid analysis for potential tumor and molecular markers may help to improve the overall accuracy of EUS FNA in the diagnosis of mucinous PCLs.
